{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:16Z","timestamp":1789824736892,"version":"4.0.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,17]],"date-time":"2013-02-17T00:00:00Z","timestamp":1361059200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Fibroblast growth factor-23 (FGF-23), a novel marker of bone disease in chronic kidney disease (CKD) has been shown to correlate with vascular calcifications. We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Pediatric and young adult patients with CKD stages I-V were recruited in this cross sectional study to measure FGF-23, cystatin C, vitamin D-metabolites and other serum markers of bone metabolism. FGF-23 levels were determined with an enzyme-linked immunosorbent assay. The association between FGF-23 and (Ca*P) was assessed using non-parametric methods. Patients were divided into two age groups, less than 13 years of age and greater than 13 years of age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This cross-sectional study measured serum FGF-23, in 81 patients (42 females, 51.9%) at London Health Sciences Centre, aged 2 to 25 years, with various stages of CKD (Cystatin C estimated glomerular filtration rate, eGFR=10.7-213.0 ml\/min). For the whole entire group of patients, FGF-23 levels were found to correlate significantly with age (Spearman r= 0.26, p=0.0198), Cystatin C eGFR (Spearman r=\u22120.40 p=0.0002), CKD stage (Spearman r=0.457, p&lt;0.0001), PTH (Spearman r=0.330, p=0.0039), ionized calcium (Spearman r=\u22120.330, p=0.0049), CysC (Spearman r= 0.404, p=0.0002) and 1,25-dihydroxyvitamin D (Spearman r=\u22120.345, p=0.0034) concentrations. No significant correlation was found between FGF-23 levels and calcium phosphate product (Spearman r= 0.164, p=0.142). Upon classification of patients into two age groups, less than 13 years of age and more than 13 years of age, correlational results differed significantly. FGF-23 correlated with CysC eGFR( Spearman r= \u22120.633, p&lt;0.0001), CKD stage (Spearman r=0.731, p&lt;0.0001), phosphate (Spearman r= 0.557, p&lt;0.0001), calcium phosphate product (Spearman r=0.534, p&lt;0.0001), 125(OH)2 Vit D (Spearman r=\u22120.631, p&lt;0.0001), PTH (Spearman r= 0.475, p=0.0017) and ionized calcium (Spearman r= \u22120.503, p=0.0015) only in the older group. The relationship between FGF-23 and Ca*P for the older group could be expressed by the exponential model FGF-23= 38.15 e<jats:sup>0.4625Ca*P<\/jats:sup>.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Abnormal values of FGF-23 in adolescents and young adults with CKD correlate with Ca* P in the absence of vascular calcifications, and may serve as a biomarker for the risk of cardiovascular calcifications.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-14-39","type":"journal-article","created":{"date-parts":[[2013,2,18]],"date-time":"2013-02-18T19:23:11Z","timestamp":1361215391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study"],"prefix":"10.1186","volume":"14","author":[{"given":"Abeer","family":"Yasin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Madrenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Filler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,17]]},"reference":[{"key":"464_CR1","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1093\/ndt\/gfm347","volume":"22","author":"PA Westerberg","year":"2007","unstructured":"Westerberg PA, Linde T, Wikstrom B, Ljunggren O, Stridsberg M, Larsson TE: Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant. 2007, 22: 3202-3207. 10.1093\/ndt\/gfm347.","journal-title":"Nephrol Dial Transplant"},{"key":"464_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.2215\/CJN.08241109","volume":"5","author":"P Evenepoel","year":"2010","unstructured":"Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, Vanderschueren D, Vanrenterghem Y: Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010, 5: 1268-1276. 10.2215\/CJN.08241109.","journal-title":"Clin J Am Soc Nephrol"},{"key":"464_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","volume":"45","author":"RC Pereira","year":"2009","unstructured":"Pereira RC, Juppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K: Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009, 45: 1161-1168. 10.1016\/j.bone.2009.08.008.","journal-title":"Bone"},{"key":"464_CR4","volume-title":"Hemodial Int","author":"RM Holden","year":"2011","unstructured":"Holden RM, Beseau D, Booth SL, Adams MA, Garland JS, Morton RA, Collier CP, Foley RN: FGF-23 is associated with cardiac troponin T and mortality in hemodialysis patients. Hemodial Int. 2011, in press"},{"key":"464_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(01)06299-7","volume":"358","author":"WG Goodman","year":"2001","unstructured":"Goodman WG: Vascular calcification in chronic renal failure. Lancet. 2001, 358: 1115-1116. 10.1016\/S0140-6736(01)06299-7.","journal-title":"Lancet"},{"key":"464_CR6","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1007\/s00467-003-1156-7","volume":"18","author":"RD Sheth","year":"2003","unstructured":"Sheth RD, Perez MD, Goldstein SL: Cardiovascular calcifications in pediatric patients receiving maintenance dialysis. Pediatr Nephrol. 2003, 18: 810-813. 10.1007\/s00467-003-1156-7.","journal-title":"Pediatr Nephrol"},{"key":"464_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1399-3046.2010.01439.x","volume":"15","author":"G Filler","year":"2011","unstructured":"Filler G: Challenges in pediatric transplantation: the impact of chronic kidney disease and cardiovascular risk factors on long-term outcomes and recommended management strategies. Pediatr Transplant. 2011, 15: 25-31. 10.1111\/j.1399-3046.2010.01439.x.","journal-title":"Pediatr Transplant"},{"key":"464_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000245042","volume":"29","author":"G Cianciolo","year":"2010","unstructured":"Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S: Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?. Blood Purif. 2010, 29: 13-22. 10.1159\/000245042.","journal-title":"Blood Purif"},{"key":"464_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11255-008-9462-4","volume":"40","author":"F Kojima","year":"2008","unstructured":"Kojima F, Uchida K, Ogawa T, Tanaka Y, Nitta K: Plasma levels of fibroblast growth factor-23 and mineral metabolism in diabetic and non-diabetic patients on chronic hemodialysis. Int Urol Nephrol. 2008, 40: 1067-1074. 10.1007\/s11255-008-9462-4.","journal-title":"Int Urol Nephrol"},{"key":"464_CR10","volume-title":"Osteoporos Int","author":"L Desjardins","year":"2011","unstructured":"Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke HD, Choukroun G, Drueke TB, Massy ZA: FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011, in press"},{"key":"464_CR11","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"34","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000, 34: 1478-83.","journal-title":"N Engl J Med"},{"key":"464_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MA Mirza","year":"2009","unstructured":"Mirza MA, Larsson A, Lind L, Larsson TE: Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009, 205: 385-390. 10.1016\/j.atherosclerosis.2009.01.001.","journal-title":"Atherosclerosis"},{"key":"464_CR13","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/ndt\/gfr208","volume":"26","author":"J Bernheim","year":"2011","unstructured":"Bernheim J, Benchetrit S: The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant. 2011, 26: 2433-2438. 10.1093\/ndt\/gfr208.","journal-title":"Nephrol Dial Transplant"},{"key":"464_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.clinbiochem.2011.01.009","volume":"44","author":"G Filler","year":"2011","unstructured":"Filler G, Liu D, Huang SH, Casier S, Chau LA, Madrenas J: Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease. Clin Biochem. 2011, 44: 435-437. 10.1016\/j.clinbiochem.2011.01.009.","journal-title":"Clin Biochem"},{"key":"464_CR15","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005, 16: 2205-2215. 10.1681\/ASN.2005010052.","journal-title":"J Am Soc Nephrol"},{"key":"464_CR16","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/ASN.2010121251","volume":"22","author":"MH de Borst","year":"2011","unstructured":"de Borst MH, Vervloet MG, Ter Wee PM, Navis G: Cross Talk Between the Renin-Angiotensin-Aldosterone System and Vitamin D-FGF-23-klotho in Chronic Kidney Disease. J Am Soc Nephrol. 2011, 22: 1603-1609. 10.1681\/ASN.2010121251.","journal-title":"J Am Soc Nephrol"},{"key":"464_CR17","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1210\/jc.2009-1576","volume":"95","author":"J Bacchetta","year":"2010","unstructured":"Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, Carlier MC, Richard M, Cochat P: The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab. 2010, 95: 1741-1748. 10.1210\/jc.2009-1576.","journal-title":"J Clin Endocrinol Metab"},{"key":"464_CR18","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00467-011-1822-0","volume":"26","author":"PR Srivaths","year":"2011","unstructured":"Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED: Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011, 26: 945-951. 10.1007\/s00467-011-1822-0.","journal-title":"Pediatr Nephrol"},{"key":"464_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/ndt\/gfp699","volume":"25","author":"JH Ix","year":"2010","unstructured":"Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010, 25: 993-997. 10.1093\/ndt\/gfp699.","journal-title":"Nephrol Dial Transplant"},{"key":"464_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00467-003-1271-5","volume":"18","author":"G Filler","year":"2003","unstructured":"Filler G, Lepage N: Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula?. Pediatr Nephrol. 2003, 18: 981-985. 10.1007\/s00467-003-1271-5.","journal-title":"Pediatr Nephrol"},{"key":"464_CR21","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s00467-011-1894-x","volume":"26","author":"G Filler","year":"2011","unstructured":"Filler G, Huang SH, Sharma AP: Should we consider MMF therapy after rituximab for nephrotic syndrome?. Pediatr Nephrol. 2011, 26: 1759-62. 10.1007\/s00467-011-1894-x.","journal-title":"Pediatr Nephrol"},{"key":"464_CR22","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab. 2002, 87: 4957-4960. 10.1210\/jc.2002-021105.","journal-title":"J Clin Endocrinol Metab"},{"key":"464_CR23","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/sj.ki.5001608","volume":"70","author":"H Wong","year":"2006","unstructured":"Wong H, Mylrea K, Feber J, Drukker A, Filler G: Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int. 2006, 70: 585-590.","journal-title":"Kidney Int"},{"key":"464_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/00365510903359245","volume":"70","author":"P Magnusson","year":"2010","unstructured":"Magnusson P, Hansson S, Swolin-Eide D: A prospective study of fibroblast growth factor-23 in children with chronic kidney disease. Scand J Clin Lab Invest. 2010, 70: 15-20.","journal-title":"Scand J Clin Lab Invest"},{"key":"464_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s00467-011-1870-5","volume":"26","author":"E Siomou","year":"2011","unstructured":"Siomou E, Challa A, Printza N, Giapros V, Petropoulou F, Mitsioni A, Papachristou F, Stefanidis CJ: Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol. 2011, 26: 1105-1114. 10.1007\/s00467-011-1870-5.","journal-title":"Pediatr Nephrol"},{"key":"464_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1210\/jc.2008-0326","volume":"94","author":"K Wesseling-Perry","year":"2009","unstructured":"Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, Juppner H, Salusky IB: Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab. 2009, 94: 511-517. 10.1210\/jc.2008-0326.","journal-title":"J Clin Endocrinol Metab"},{"key":"464_CR27","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1093\/ndt\/gfr126","volume":"26","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, Salusky IB: Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?. Nephrol Dialysis Transplant. 2011, 26: 3779-84. 10.1093\/ndt\/gfr126.","journal-title":"Nephrol Dialysis Transplant"},{"key":"464_CR28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1399-3046.2011.01613.x","volume":"16","author":"G Filler","year":"2012","unstructured":"Filler G, Liu D, Sharma AP, Grimmer J: Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients?. Pediatr Transplant. 2012, 16: 73-77. 10.1111\/j.1399-3046.2011.01613.x.","journal-title":"Pediatr Transplant"},{"key":"464_CR29","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","volume":"64","author":"T Larsson","year":"2003","unstructured":"Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003, 64: 2272-2279. 10.1046\/j.1523-1755.2003.00328.x.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-14-39\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-39","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-39.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:27:28Z","timestamp":1630535248000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-14-39"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,17]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["464"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-14-39","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,17]]},"assertion":[{"value":"29 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"39"}}